• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2大流行中的免疫功能障碍与多种治疗方式:失控的赛跑汗水之种种?

Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?

作者信息

Kothari Ashish, Singh Vanya, Nath Uttam Kumar, Kumar Sandeep, Rai Vineeta, Kaushal Karanvir, Omar Balram Ji, Pandey Atul, Jain Neeraj

机构信息

Department of Microbiology, All India Institute of Medical Sciences, Rishikesh 249203, India.

Department of Medical Oncology & Hematology, All India Institute of Medical Sciences, Rishikesh 249203, India.

出版信息

Biology (Basel). 2020 Aug 24;9(9):243. doi: 10.3390/biology9090243.

DOI:10.3390/biology9090243
PMID:32846906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7563789/
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global pandemic threat with more than 11.8 million confirmed cases and more than 0.5 million deaths as of 3 July 2020. Given the lack of definitive pharmaceutical interventions against SARS-CoV-2, multiple therapeutic strategies and personal protective applications are being used to reduce the risk of high mortality and community spread of this infection. Currently, more than a hundred vaccines and/or alternative therapeutic regimens are in clinical trials, and some of them have shown promising results in improving the immune cell environment and controlling the infection. In this review, we discussed high-performance multi-directory strategies describing the uncontrolled deregulation of the host immune landscape associated with coronavirus disease (COVID-19) and treatment strategies using an anti-neoplastic regimen. We also followed selected current treatment plans and the most important on-going clinical trials and their respective outcomes for blocking SARS-CoV-2 pathogenesis through regenerative medicine, such as stem cell therapy, chimeric antigen receptors, natural killer (NK) cells, extracellular vesicular-based therapy, and others including immunomodulatory regimens, anti-neoplastic therapy, and current clinical vaccine therapy.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发了全球大流行威胁,截至2020年7月3日,确诊病例超过1180万例,死亡人数超过50万。鉴于缺乏针对SARS-CoV-2的确定性药物干预措施,目前正在采用多种治疗策略和个人防护措施来降低这种感染导致高死亡率和社区传播的风险。目前,有一百多种疫苗和/或替代治疗方案正在进行临床试验,其中一些在改善免疫细胞环境和控制感染方面已显示出有前景的结果。在本综述中,我们讨论了高性能多目录策略,描述了与冠状病毒病(COVID-19)相关的宿主免疫格局的失控失调以及使用抗肿瘤方案的治疗策略。我们还跟踪了当前选定的治疗方案以及通过再生医学(如干细胞疗法、嵌合抗原受体、自然杀伤(NK)细胞、基于细胞外囊泡的疗法等)以及包括免疫调节方案、抗肿瘤疗法和当前临床疫苗疗法在内的其他疗法来阻断SARS-CoV-2发病机制的最重要的正在进行的临床试验及其各自结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d9/7563789/396e9e888593/biology-09-00243-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d9/7563789/396e9e888593/biology-09-00243-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d9/7563789/396e9e888593/biology-09-00243-g001.jpg

相似文献

1
Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?SARS-CoV-2大流行中的免疫功能障碍与多种治疗方式:失控的赛跑汗水之种种?
Biology (Basel). 2020 Aug 24;9(9):243. doi: 10.3390/biology9090243.
2
Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.从分子机制和免疫反应角度治疗新冠肺炎的当前方法。
Saudi Pharm J. 2020 Nov;28(11):1333-1352. doi: 10.1016/j.jsps.2020.08.024. Epub 2020 Sep 1.
3
Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.SARS-CoV、MERS-CoV 和 SARS-CoV-2 感染中的免疫致病反应和血液病理效应的重点。
Front Immunol. 2020 May 12;11:1022. doi: 10.3389/fimmu.2020.01022. eCollection 2020.
4
Current status in cellular-based therapies for prevention and treatment of COVID-19.用于 COVID-19 预防和治疗的基于细胞的疗法的现状。
Crit Rev Clin Lab Sci. 2023 Aug;60(5):321-345. doi: 10.1080/10408363.2023.2177605. Epub 2023 Feb 23.
5
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.多发性硬化症的疾病修正治疗与 COVID-19 大流行:感染风险和未来疫苗接种的影响。
CNS Drugs. 2020 Sep;34(9):879-896. doi: 10.1007/s40263-020-00756-y.
6
Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.设计治疗策略以对抗严重急性呼吸综合征冠状病毒 2 型疾病:COVID-19。
Drug Dev Res. 2021 Feb;82(1):12-26. doi: 10.1002/ddr.21720. Epub 2020 Jul 30.
7
Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy.应对新冠疫情时代的挑战:从标准治疗到脐带间充质干细胞的新治疗策略。
Cells. 2023 Jun 19;12(12):1664. doi: 10.3390/cells12121664.
8
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.SARS-CoV-2 变体和 COVID-19 疫苗:当前的挑战与未来策略。
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
9
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.新型冠状病毒对造血干细胞移植和嵌合抗原受体 T 细胞治疗受者的影响。
Transplant Cell Ther. 2021 Sep;27(9):796.e1-796.e7. doi: 10.1016/j.jtct.2021.07.005. Epub 2021 Jul 10.
10
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.扩充脐带间充质干细胞(UC-MSCs)作为治疗危重症 COVID-19 患者的一种治疗策略:同情用药的理由。
Pain Physician. 2020 Mar;23(2):E71-E83.

引用本文的文献

1
Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.间充质干细胞治疗 COVID-19 的临床试验。
Curr Stem Cell Res Ther. 2024;19(8):1055-1071. doi: 10.2174/011574888X260032230925052240.
2
Coronavirus Disease 2019 (COVID-19).2019冠状病毒病(COVID-19)
Biology (Basel). 2022 Aug 22;11(8):1250. doi: 10.3390/biology11081250.
3
Mixed invasive fungal infections among COVID-19 patients.新冠病毒肺炎患者中的混合性侵袭性真菌感染

本文引用的文献

1
Single-Cell Transcriptome Analysis Decipher New Potential Regulation Mechanism of ACE2 and NPs Signaling Among Heart Failure Patients Infected With SARS-CoV-2.单细胞转录组分析揭示感染SARS-CoV-2的心力衰竭患者中ACE2和NPs信号传导的新潜在调控机制。
Front Cardiovasc Med. 2021 Feb 23;8:628885. doi: 10.3389/fcvm.2021.628885. eCollection 2021.
2
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.新冠病毒肺炎患者中中和抗体反应的快速产生
Cell Rep Med. 2020 Jun 23;1(3):100040. doi: 10.1016/j.xcrm.2020.100040. Epub 2020 Jun 8.
3
Covid-19: Russia approves vaccine without large scale testing or published results.
Curr Med Mycol. 2021 Dec;7(4):19-27. doi: 10.18502/cmm.7.4.8407.
4
Induced pluripotent stem cell-based disease modeling and prospective immune therapy for coronavirus disease 2019.基于诱导多能干细胞的 2019 冠状病毒病疾病建模和前瞻性免疫治疗。
Cytotherapy. 2022 Mar;24(3):235-248. doi: 10.1016/j.jcyt.2021.08.003. Epub 2021 Sep 14.
5
An Eventual Sars-CoV-2 Infection Prevention Protocol in the Medical Setting and Dental Office.医疗机构和牙科诊所中最终的新型冠状病毒2感染预防方案。
Int J Environ Res Public Health. 2021 Mar 5;18(5):2593. doi: 10.3390/ijerph18052593.
新冠疫情:俄罗斯未经大规模测试或公布结果就批准了疫苗。
BMJ. 2020 Aug 13;370:m3205. doi: 10.1136/bmj.m3205.
4
The Controversy of Renin-Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection.肾素-血管紧张素-系统阻滞剂促进与对抗 COVID-19 感染的争议。
J Cardiovasc Pharmacol. 2020 Oct;76(4):397-406. doi: 10.1097/FJC.0000000000000894.
5
Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using Structure-Based Virtual Screening Approach.基于结构的虚拟筛选方法通过药物再利用鉴定 SARS-CoV-2 细胞进入抑制剂。
Front Immunol. 2020 Jul 10;11:1664. doi: 10.3389/fimmu.2020.01664. eCollection 2020.
6
Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.芦可替尼用于治疗对托珠单抗难治的重症COVID-19感染。
Br J Haematol. 2020 Aug;190(4):e198-e200. doi: 10.1111/bjh.16979. Epub 2020 Jul 26.
7
Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases.间充质干细胞及其外泌体在重症新型冠状病毒肺炎(COVID-19)病例中的治疗潜力
Inflamm Regen. 2020 Jun 22;40:14. doi: 10.1186/s41232-020-00121-y. eCollection 2020.
8
Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients.依托泊苷作为免疫抑制剂的辅助治疗用于危重症COVID-19患者。
J Infect. 2020 Sep;81(3):452-482. doi: 10.1016/j.jinf.2020.06.006. Epub 2020 Jun 21.
9
VEGF-D: a novel biomarker for detection of COVID-19 progression.血管内皮生长因子-D:一种用于检测新冠病毒疾病进展的新型生物标志物。
Crit Care. 2020 Jun 23;24(1):373. doi: 10.1186/s13054-020-03079-y.
10
Exportin 1 inhibition as antiviral therapy.Exportin 1 抑制作为抗病毒疗法。
Drug Discov Today. 2020 Oct;25(10):1775-1781. doi: 10.1016/j.drudis.2020.06.014. Epub 2020 Jun 20.